Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FibroGen Inc.

www.fibrogen.com

Latest From FibroGen Inc.

Pipeline Watch: Phase III Readouts For ADV7103, Pembrolizumab, Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deals Shaping The Medical Industry, September 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Deals Medical Device

Deal Watch: Inventiva Expands Collaborations With Boehringer, AbbVie

French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.

Deals M & A

Finance Watch: 2Q Brings Cost Cuts, Strategic Reviews For Many Biotechs

Peregrine, Ardelyx, Egalet and others reduced expenses and sought alternatives in the second quarter. Also, cell and gene therapy investment rises, FibroGen priced a $326m offering and Unity increased its Series B by $35m.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Hepatic (Liver)
  • Musculoskeletal & Connective Tissue Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • FibroGen Inc.
  • Senior Management
  • Thomas B Neff, Chmn. & CEO
    Pat Cotroneo, VP, Fin. & CFO
    David M Dimmick, MD, VP, Quality
    R. Wayne Frost, VP, RA
    Elias Kouchakji, MD, VP, Clinical Dev and Drug Safety
    AI Lin, MD, PhD, VP, Drug Dev.
    Peony K Yu, CMO
  • Contact Info
  • FibroGen Inc.
    Phone: (415) 978-1200
    409 Illinois St.
    San Francisco, CA 94158
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register